Q1 2025 PAVmed Inc Earnings Call Transcript

May 15, 2025 / 12:30 PM GMT

Release Date Price: €2.64

Transcript 8-K10-Q

Key Points

Positve

PAVmed Inc (PAVM) has successfully stabilized its corporate structure and balance sheet, positioning itself as a diversified commercial life science company.
The company reported a significant strengthening of its balance sheet with a public offering netting $16.1 million, extending its financial runway well into 2026.
Lucid, a subsidiary of PAVmed Inc (PAVM), is on the cusp of key milestones, including Medicare coverage, and reported revenue of $800,000 with test volumes at the upper end of their target range.
PAVmed Inc (PAVM) has secured financing to restart development of a critical implantable monitor for its subsidiary, Veris, and is close to finalizing a strategic partnership.
The company is actively pursuing expansion into the biopharma space, leveraging its infrastructure and track record to explore attractive assets and partnerships.

Negative

PAVmed Inc (PAVM) faces uncertainties related to forward-looking statements, which are subject to risks that could cause actual results to differ materially.
The company is still awaiting a response from the Medicare program regarding coverage for its e-cigarette diagnostic, which is crucial for accelerating commercialization.
There are significant differences in financial reporting due to the deconsolidation of Lucid, which may blur historical understanding of PAVmed Inc (PAVM)'s financials.
The company has a complex corporate structure with multiple subsidiaries, which may pose challenges in management and strategic alignment.
PAVmed Inc (PAVM) is pursuing multiple initiatives simultaneously, including expansion into biopharma, which could stretch its resources and focus.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

PAVM.OQ - PAVmed Inc
Q1 2025 PAVmed Inc Earnings Call
May 15, 2025 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning and welcome to the PAMed first quarter 2025 business update conference call. At this time, all lines are in listen-only.

Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press 0 for the operator. Please note this event is being recorded. I would now like to turn the conference over to Matt Riley. I have met senior director of investor relations. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator, and good morning everyone.

Thank you for

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.